Page last updated: 2024-11-05

glucosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439213
CHEMBL ID493287
CHEBI ID47977
CHEBI ID17315
CHEBI ID5417
SCHEMBL ID167831
MeSH IDM0009332

Synonyms (55)

Synonym
glucosamina [inn-spanish]
glucosaminum [inn-latin]
glucosamine [usan:inn]
2 amino 2 deoxyglucose
glucosamine (usan/inn)
D04334
GLUCOSAMINE ,
d-glucosamine
C00329
chitosamine
2-amino-2-deoxy-d-glucose
DB01296
CHEBI:47977 ,
BMSE000247
(3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
STK801823
2-amino-2-deoxy-d-glucopyranose
AKOS005622471
BBL009288
d-glucopyranose, 2-deoxy-2-amino-
90-77-7
CHEMBL493287
2-amino-2-deoxy-glucose
(3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)tetrahydro-2h-pyran-2,4,5-triol
EPITOPE ID:151531
glcnh2
SCHEMBL167831
2-amino-2-deoxyhexopyranose #
2-deoxy-2-amino-glucopyranose
2-deoxy-2-amino-glucopyranoside
d-glcn
2-deoxy-2-amino-d-glucose
GLCN ,
2-deoxy-2-amino-d-glucopyranose
2-amino-2-deoxy-d-glucopyranoside
2-deoxy-2-amino-d-glucopyranoside
2-amino-2-deoxy-glucopyranose
2-deoxy-2-amino-glucose
2-amino-2-deoxy-glucopyranoside
2-deoxy-2-aminoglucose
(+)-2-amino-2-deoxy-d-glucopyranose
glucosamin
J-019472
Q327506
d-glucosamine;chitosamine
3416-24-8 (free base)
glucosamine free base
F88954
glukosamin
glucosaminum (inn-latin)
chebi:17315
glucosamina (inn-spanish)
wurcs=2.0/1,1,0/(a2122h-1x_1-5_2*n)/1/
chebi:5417
dtxcid203098

Research Excerpts

Toxicity

Glucosamine hydrochloride is as effective and safe as glucosamine sulfate for the treatment of osteoarthritis. The carboxylic acid moiety present in common NSAIDs is responsible for some of their adverse effects, but is not required for their anti-inflammatory activity.

ExcerptReferenceRelevance
" This indicated that the adverse effects that these conditions have on the anticoagulant properties of heparin are not specifically associated with the 3-sulfate substituent of residues of 6 in the polymer."( Adverse effects of alkali and acid on the anticoagulant potency of heparin, evaluated with methyl 2-deoxy-2-sulfamino-alpha-D-glucopyranoside 3-sulfate as a model compound.
Liu, Z; Perlin, AS, 1992
)
0.28
" Pericarditis as a side effect induced by sulfasalazine or 5-aminosalicylic acid, drugs used in the therapy of these diseases, was first described only 7 years ago."( [Pericarditis in chronic inflammatory bowel disease: underlying disease or side effects of therapy? Clinical problem solving].
Krähenbühl, S; Kupferschmidt, H; Langenegger, T, 1996
)
0.29
"Miglitol monotherapy is effective and safe in NIDDM patients."( The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Berlin, C; Feig, PU; Petzinna, D; Ratzmann, KP; Rybka, J; Schernthaner, G; Segal, P, 1997
)
0.3
" Knee pain at rest, at movement and at pressure, knee swelling, improvement and therapeutic utility as well as adverse events and drop-outs were recorded after 2 and 4 weeks of treatment."( Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis.
Gao, SN; Giacovelli, G; Qiu, GX; Rovati, L; Setnikar, I, 1998
)
0.3
" The LD50 of oral glucosamine in animals is approximately 8000 mg/kg with no adverse effects at 2700 mg/kg for 12 months."( Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy.
Anderson, JW; Borzelleca, JF; Nicolosi, RJ, 2005
)
0.33
" Three cases in study group and 2 in control group reported mild adverse events."( [Efficacy and safety evaluation of glucosamine hydrochloride in the treatment of osteoarthritis].
Chen, XL; Li, JM; Yang, ZP; Zhang, WB; Zhuang, CY, 2007
)
0.34
"Glucosamine hydrochloride is as effective and safe as glucosamine sulfate for the treatment of osteoarthritis."( [Efficacy and safety evaluation of glucosamine hydrochloride in the treatment of osteoarthritis].
Chen, XL; Li, JM; Yang, ZP; Zhang, WB; Zhuang, CY, 2007
)
0.34
" The results of this study suggest that the oral chondroprotective agent tested is safe for administration to horses at recommended dose rates."( Safety of an oral chondroprotective agent in horses.
Kirker-Head, CA; Kirker-Head, RP, 2001
)
0.31
" Adverse reactions were similar among treatment groups and serious adverse events were rare for all treatments."( Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT.
Bingham, CO; Bradley, JD; Clegg, DO; Dunlop, DD; Finco, MF; Furst, DE; Harris, CL; Jackson, CG; Lane, NE; Lisse, J; Moskowitz, RW; Oddis, CV; Reda, DJ; Sawitzke, AD; Shi, H; Silver, D; Singer, NG; Williams, HJ; Wolfe, F, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 6 for both patients) between the patients' development of hepatotoxicity and the Move Free Advanced supplement."( Hepatotoxicity associated with chinese skullcap contained in Move Free Advanced dietary supplement: two case reports and review of the literature.
Linnebur, SA; Rapacchietta, OC; Vejar, M, 2010
)
0.36
" However, the oligomers obtained after hydrolysis demonstrated no toxic effects on the normal cells (3T3)."( Chitooligosaccharides antagonize the cytotoxic effect of glucosamine.
Costa, LS; de Assis, CF; de Macedo, GR; Melo-Silveira, RF; Oliveira, RM; Pagnoncelli, MG; Rocha, HA; Santos, ES, 2012
)
0.38
"To conduct a systematic review and network meta-analysis of randomized controlled trials (RCTs) with the aims of comparing relevant clinical outcomes (that is, visual analog scores (VAS), total and sub-Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) scores, Lequesne algofunctional index, joint space width change, and adverse events) between diacerein, glucosamine, and placebo."( Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis.
Anothaisintawee, T; Attia, J; Kongtharvonskul, J; McEvoy, M; Thakkinstian, A; Woratanarat, P, 2015
)
0.42
" Although no significant difference was observed among the five options with respect to the three major adverse effects (withdrawal due to adverse events, serious adverse events and the number of patients with adverse events), the additional classical meta-analysis showed that celecoxib exhibited a higher rate of gastrointestinal adverse effect comparing with the placebo group."( Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee.
Gao, SG; Lei, GH; Li, H; Li, YS; Luo, W; Wang, YL; Wei, J; Xie, DX; Yang, T; Zeng, C, 2015
)
0.42
" Adverse events and drug tolerability were analyzed."( Multicenter, randomized, double-blind clinical trial to evaluate efficacy and safety of combined glucosamine sulfate and chondroitin sulfate capsules for treating knee osteoarthritis.
Castro, ML; de Castro Brandão, G; Lomonte, ABV; Mendonça, JA, 2018
)
0.48
" Adverse events were similar between groups and both presented good tolerability."( Multicenter, randomized, double-blind clinical trial to evaluate efficacy and safety of combined glucosamine sulfate and chondroitin sulfate capsules for treating knee osteoarthritis.
Castro, ML; de Castro Brandão, G; Lomonte, ABV; Mendonça, JA, 2018
)
0.48
" The proved effect of NSAIDS must always correlate with the side effect risk."( Use of a glycosamine sulfate for patients with osteoarthritis and a comorbidity with high risk of the side effects from NSAIDS.
Naumov, AV; Tkacheva, ON, 2018
)
0.48
" The current work shows that antioxidant additives can reduce the toxic effect of CPAs on porcine chondrocytes."( Evaluation of five additives to mitigate toxicity of cryoprotective agents on porcine chondrocytes.
Dong, R; Elliott, JAW; Jomha, NM; Laouar, L; Wu, K, 2019
)
0.51
"Acute oral toxicity of m-PGA resulted in LD50 values in excess of 2000 mg/kg."( Safety and efficacy of a new micronized formulation of the ALIAmide palmitoylglucosamine in preclinical models of inflammation and osteoarthritis pain.
Cordaro, M; Crupi, R; Cuzzocrea, S; D' Amico, R; Di Paola, R; Fusco, R; Gugliandolo, E; Impellizzeri, D; Peritore, AF; Schievano, C; Siracusa, R, 2019
)
0.51
" In other words, which compounds are least likely to cause harm, while still potentially providing benefit? To systematically answer this question we queried the DrugAge database-containing hundreds of known geroprotectors-and cross-referenced this with a recently published repository of compound side effect predictions."( Identification of longevity compounds with minimized probabilities of side effects.
Houtkooper, RH; Janssens, GE, 2020
)
0.56
" Thus, GlukvamineTM is a promising effective and safe drug for pharmacological correction of the hepatotoxicity of MTX."( The hepatoprotective effect of the combination of glucosamine derivatives with quercetin against methotrexate-induced liver toxicity.
Sakharova, TS; Vietrova, KV; Zupanets, IA, 2020
)
0.56
" As the carboxylic acid moiety present in common NSAIDs is responsible for some of their adverse effects, but is not required for their anti-inflammatory activity, we sought to mask this group through direct coupling to glucosamine, which is thought to prevent cartilage degradation."( Molecular docking-guided synthesis of NSAID-glucosamine bioconjugates and their evaluation as COX-1/COX-2 inhibitors with potentially reduced gastric toxicity.
Hall, CD; Jones Lipinski, RA; Katritzky, AR; Morisseau, C; Sebastiano, CS; Smith, BC; Thillier, Y, 2021
)
0.62

Pharmacokinetics

Study was conducted to assess and compare the pharmacokinetic properties, bioavailability of a newly developed dispersible tablet formulation (test) of glucosamine hydrochloride.

ExcerptReferenceRelevance
" The procedure was applied to pharmacokinetics in the dog and a two-compartment body model was observed with a terminal half-life of 103-130 min."( Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride.
Garrett, ER; Mahrous, H; Schuermann, W; Van Peer, A, 1982
)
0.26
" administration similar pharmacokinetic patterns are observed."( Pharmacokinetics of glucosamine in man.
Canali, S; Palumbo, R; Setnikar, I; Zanolo, G, 1993
)
0.29
"This was a double-blind, randomised, placebo-controlled, cross-over study to determine the possible pharmacodynamic and pharmacokinetic interaction of miglitol (CAS 72432-03-2, Bay m 1099) and warfarin sodium (CAS 129-06-6) in healthy volunteers."( Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
Duursema, L; Groenewoud, G; Hundt, HK; Middle, MV; Müller, FO; Schall, R, 1996
)
0.29
"After intravenous administration, the apparent terminal half-life (1."( Single dose pharmacokinetics and bioavailability of glucosamine in the rat.
Aghazadeh-Habashi, A; Jamali, F; Pasutto, F; Sattari, S,
)
0.13
" Pharmacokinetic analysis was performed on glucosamine and total chondroitin sulfate disaccharides and parameters were compared across treatments using ANOVA with post hoc analysis."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs.
Adebowale, A; Du, J; Eddington, ND; Leslie, JL; Liang, Z, 2002
)
0.31
" Blood samples were collected, assayed and pharmacokinetic parameters were determined."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse.
Du, J; Eddington, ND; White, N, 2004
)
0.32
" This method proved to be simple, reproducible and feasible for pharmacokinetic studies of glucosamine sulfate in healthy volunteers after a single oral administration (1500 mg)."( Liquid chromatography with electrospray ionization mass spectrometry method for the assay of glucosamine sulfate in human plasma: validation and application to a pharmacokinetic study.
Cai, L; Duan, GL; Huang, TM; Shen, YF; Yang, B; Zhou, MX, 2006
)
0.33
" Pharmacokinetic parameters were calculated at steady state."( Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man.
Giacovelli, G; Locatelli, M; Persiani, S; Roda, A; Roda, E; Rovati, LC, 2005
)
0.33
" The validated method was successfully applied for the quantitative determination of glucosamine in rat plasma and evaluation for pharmacokinetic study of glucosamine."( Optimizing high-performance liquid chromatography method for quantification of glucosamine using 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate derivatization in rat plasma: application to a pharmacokinetic study.
Chen, L; Chen, X; He, C; Hu, J; Li, R; Peng, C; Tang, M; Wang, B; Wang, X; Wei, Y; Zhang, F; Zhao, X, 2008
)
0.35
" A two-compartment pharmacokinetic model was used."( Glucosamine sulfate effect on the degenerated patellar cartilage: preliminary findings by pharmacokinetic magnetic resonance modeling.
Alberich-Bayarri, A; Carot, JM; Martí-Bonmatí, L; Rodrigo, JL; Sanz-Requena, R, 2009
)
0.35
" On the other hand, the Cmax (single-dose study) and AUC values (multiple-dose study) for ingested GlcN were significantly reduced by combination dosing with CS, relative to GlcN dosing alone."( The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.
Barnhill, JG; Clegg, DO; Harris, CL; Hua, C; Jackson, CG; Kim-Rolands, S; Plaas, AH; Sandy, JD, 2010
)
0.36
" Subsequently, a 25mg/kg verapamil administered, electrocardiographs were recorded and pharmacokinetic delineated."( Glucosamine and adjuvant arthritis: a pharmacokinetic and pharmacodynamic study.
Gilzad-Kohan, MH; Jamali, F, 2012
)
0.38
" This study was conducted to assess and compare the pharmacokinetic (PK) properties, bioavailability of a newly developed dispersible tablet formulation (test) of glucosamine hydrochloride with those of an established branded capsule formulation (reference) in healthy Chinese adult male volunteers."( Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers.
Feng, W; Liu, M; Tang, Y; Wang, S; Wei, M; Wu, H; Yan, M; Yao, W; Zhao, H, 2012
)
0.38
" The main pharmacokinetic parameters were calculated (Cmax, tmax, AUC)."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
0.43
"7 ng/mL), while tmax values were similar for the three folate forms."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
0.43
" The pharmacokinetic parameters at steady state [including the minimum (Css min) and maximum (Css max) plasma concentration of glucosamine, time to reach Css max post-dosing (Tss max) and area under the plasma concentration vs time curve (AUCss 0-12)] for each brand were calculated and statistically compared."( Variation in the pharmacokinetics of glucosamine in healthy individuals.
Asthana, C; Patel, RP; Peterson, GM; Shastri, MD, 2021
)
0.62
" No significant differences were observed in the pharmacokinetic parameters between the two brands."( Variation in the pharmacokinetics of glucosamine in healthy individuals.
Asthana, C; Patel, RP; Peterson, GM; Shastri, MD, 2021
)
0.62

Compound-Compound Interactions

Aerobic exercise combined with glucosamine hydrochloride capsules inhibited the apoptosis of chondrocytes in rabbit KOA by affecting the expression of TRPV5. The clinical efficacy of Chondroitin combined with Glucosamine was significantly better than that of routine treatment by meta-analysis.

ExcerptReferenceRelevance
"This preliminary study sought to determine whether using 1500/1200mg of glucosamine hydrochloride and chondroitin sulfate (GH/CS) is effective, both separately and combined with exercise, compared to a placebo plus exercise program in improving physical function, pain, strength, balance, and mobility in older adults with knee osteoarthritis (OA)."( Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study.
Adrian, A; Jolla, J; Legault, C; Loeser, RF; Messier, SP; Mihalko, S; Pfruender, J; Prosser, B; Williamson, JD, 2007
)
0.34
" In contrast, we demonstrate that a triple drug combination of IFN, RBV, and an iminosugar eradicated the BVDV infection in a time- and a dose-dependent manner, leading to sustained viral clearance."( Iminosugars in combination with interferon and ribavirin permanently eradicate noncytopathic bovine viral diarrhea virus from persistently infected cells.
Branza-Nichita, N; Dwek, RA; Hussey, M; Michelet, M; Smith, C; Woodhouse, SD; Zitzmann, N, 2008
)
0.35
" The present study was carried out to compare the effect of a novel agent glucosamine alendronate (GA) alone and is combination with dihydroquercetin (DHQ) against the effect of a known drug alendronate (ALN) in the senescence-accelerated OXYS rats as model of osteoporosis."( Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model.
Kolosova, NG; Muraleva, NA; Ofitserov, EN; Tikhonov, VP, 2012
)
0.38
"The objective of the present study was to investigate the effect of the fucoxanthin (FUCO) alone and in combination with glucosamine hydrochloride (GAH) on carrageenan/kaolin-induced inflammatory arthritis model in rats and to explore its underlying mechanisms."( Effect of fucoxanthin alone and in combination with D-glucosamine hydrochloride on carrageenan/kaolin-induced experimental arthritis in rats.
Chu, W; Geng, C; Gong, D; Ishikawa, N; Jiang, L; Kajima, K; Li, J; Zhong, L, 2014
)
0.4
" The aims of our study were to investigate the therapeutic efficacy of Glu in combination with low-dose CsA on imiquimod (IMQ)-induced psoriasis-like dermatitis in mice and to determine its immunomodulatory mechanism."( Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine a in a murine model of imiquimod-induced psoriasis.
Kim, CH; Kim, JY; Lee, AY, 2015
)
0.42
" A double-blinded randomized controlled trial was designed to investigate the effectiveness and safety of oral glucosamine hydrochloride pills combined with hyaluronate sodium intra-articular injection in TMJ OA."( Oral Glucosamine Hydrochloride Combined With Hyaluronate Sodium Intra-Articular Injection for Temporomandibular Joint Osteoarthritis: A Double-Blind Randomized Controlled Trial.
Li, C; Li, L; Liu, W; Miao, C; Sun, H; Yang, W, 2018
)
0.48
" Protein hydrolysates were prepared from porcine muscle and plasma through simultaneous hydrolysis using endo- and exo-peptidases combined with peptide glycation by glucosamine (GlcN)."( Exopeptidase treatment combined with Maillard reaction modification of protein hydrolysates derived from porcine muscle and plasma: Structure-taste relationship.
Bredie, WLP; Fu, Y; Hansen, ET; Lametsch, R; Liu, J; Tøstesen, M; Wæhrens, SS; Zhang, W, 2020
)
0.56
"To evaluate the repairing effects of glucosamine sulfate combined with etoricoxib on articular cartilages of patients with knee osteoarthritis (KOA)."( Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis.
Gong, C; Sun, Y; Wang, C, 2020
)
0.56
"To explore the efficacy of glucosamine sulfate (GS) combined with loxoprofen sodium (LS) in rats with knee osteoarthritis (KOA) and its effect on chondrocytes."( The inhibiting effect of glucosamine sulfate combined with loxoprofen sodium on chondrocyte apoptosis in rats with knee osteoarthritis.
Luo, M; Luo, W; Wang, Q; Xu, F, 2021
)
0.62
"GS combined with LS showed good efficacy in rats with knee osteoarthritis, which may be achieved by inhibiting the expression of inflammatory factors and knee chondrocyte apoptosis via the TLR4-NF-kB pathway."( The inhibiting effect of glucosamine sulfate combined with loxoprofen sodium on chondrocyte apoptosis in rats with knee osteoarthritis.
Luo, M; Luo, W; Wang, Q; Xu, F, 2021
)
0.62
" Aerobic exercise combined with glucosamine had a synergistic therapeutic effect on knee osteoarthritis."( The mechanism of aerobic exercise combined with glucosamine therapy and circUNK in improving knee osteoarthritis in rabbits.
Chen, B; Fang, L; Huang, Z; Lin, L; Lin, X; Lv, Y; Wang, X, 2021
)
0.62
" The aim of this study was to evaluate, by the use of force plate gait analysis, the clinical efficacy of Boswellia and Curcuvet® combined with conventional nutraceutical therapy compared with conventional nutraceutical alone in dogs affected by osteoarthritis."( Clinical efficacy of Curcuvet and Boswellic acid combined with conventional nutraceutical product: An aid to canine osteoarthritis.
Aragosa, F; Caterino, C; Costanza, D; Della Valle, G; Fatone, G; Lamagna, F; Nieddu, A; Piscitelli, A, 2021
)
0.62
"In conclusion Curcuvet in combination with Boswellic acid could be considered a valid aid in a multimodal treatment for canine osteoarthritis."( Clinical efficacy of Curcuvet and Boswellic acid combined with conventional nutraceutical product: An aid to canine osteoarthritis.
Aragosa, F; Caterino, C; Costanza, D; Della Valle, G; Fatone, G; Lamagna, F; Nieddu, A; Piscitelli, A, 2021
)
0.62
" Altogether 128 patients with knee osteoarthritis in the middle and early stage admitted to our hospital from January 2018 to July 2019 were selected and grouped into the control group (CG) (celecoxib tablet therapy) and the combination group (ComG) (celecoxib combined with glucosamine hydrochloride therapy)."( Effect of celecoxib combined with glucosamine hydrochloride in promoting the functional recovery and decreasing the inflammatory factor levels in patients with knee osteoarthritis.
Ge, R; Yang, Z; Zhang, J, 2021
)
0.62
"Presently, curcuminoid formulations or its combination with conventional therapies has been used for the treatment of knee osteoarthritis (KOA)."( The comparison of curcuminoid formulations or its combination with conventional therapies versus conventional therapies alone for knee osteoarthritis.
Kou, Q; Ren, J; Sun, W; Wan, Y; Yang, J, 2022
)
0.72
"Randomized controlled trials comparing curcuminoid formulations or its combination with conventional therapies versus conventional therapies, such as non-steroidal antiinflammatory drugs (NSAIDs) and chondroitin sulfate/glucosamine, were searched from databases."( The comparison of curcuminoid formulations or its combination with conventional therapies versus conventional therapies alone for knee osteoarthritis.
Kou, Q; Ren, J; Sun, W; Wan, Y; Yang, J, 2022
)
0.72
" Notably, curcuminoid formulations combined with NSAIDs significantly reduced VAS and WOMAC/Knee injury and OA Outcome Score (KOOS) pain score more than NSAIDs did."( The comparison of curcuminoid formulations or its combination with conventional therapies versus conventional therapies alone for knee osteoarthritis.
Kou, Q; Ren, J; Sun, W; Wan, Y; Yang, J, 2022
)
0.72
"This study aimed to investigate the effect of aerobic exercise combined with glucosamine (OTL) on the apoptosis of chondrocytes of rabbit knee osteoarthritis (KOA) by affecting the expression of TRPV5."( Aerobic exercise combined with glucosamine hydrochloride capsules inhibited the apoptosis of chondrocytes in rabbit knee osteoarthritis by affecting TRPV5 expression.
Chen, B; Fang, L; Huang, Z; Lin, L; Lin, X; Lv, Y; Wang, X, 2022
)
0.72
"Aerobic exercise combined with glucosamine hydrochloride capsules inhibited the apoptosis of chondrocytes in rabbit KOA by affecting the expression of TRPV5."( Aerobic exercise combined with glucosamine hydrochloride capsules inhibited the apoptosis of chondrocytes in rabbit knee osteoarthritis by affecting TRPV5 expression.
Chen, B; Fang, L; Huang, Z; Lin, L; Lin, X; Lv, Y; Wang, X, 2022
)
0.72
"This analysis was aimed at providing evidence-based medicine basis for systematic evaluation of chondroitin combined with glucosamine in the treatment of knee osteoarthritis."( Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis.
Chen, Y; Lu, C; Wang, R; Wang, Z; Yang, J; Yao, H; Zhu, Y, 2022
)
0.72
"The randomized controlled trials (RCTs) of chondroitin combined with glucosamine in the treatment of knee osteoarthritis (KOA) were searched in PubMed, EMBASE, ScienceDirect, Cochrane Library, China Knowledge Network Database (CNKI), China VIP Database, Wanfang Database, and China Biomedical Literature Database (CBM) online database."( Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis.
Chen, Y; Lu, C; Wang, R; Wang, Z; Yang, J; Yao, H; Zhu, Y, 2022
)
0.72
" The clinical efficacy of chondroitin combined with glucosamine was significantly better than that of routine treatment by meta-analysis."( Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis.
Chen, Y; Lu, C; Wang, R; Wang, Z; Yang, J; Yao, H; Zhu, Y, 2022
)
0.72
"Chondroitin combined with glucosamine is more effective than chondroitin or glucosamine alone in the treatment of KOA and deserves clinical promotion."( Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis.
Chen, Y; Lu, C; Wang, R; Wang, Z; Yang, J; Yao, H; Zhu, Y, 2022
)
0.72
"To investigate the effects of glucosamine hydrochloride combined with non-steroidal anti-inflammatory drugs on symptoms and HSS scores in patients with knee osteoarthritis (KOA)."( Effects of glucosamine hydrochloride combined with non-steroidal anti-inflammatory drugs on symptoms and HSS scores in patients with knee osteoarthritis.
Liu, G; Pan, H; Shi, J; Shi, Q; Wang, F; Wang, J; Zheng, S, 2023
)
0.91
"To investigate the effects of glucosamine hydrochloride combined with non-steroidal anti-inflammatory drugs on symptoms and HSS scores in patients with knee osteoarthritis (KOA)."( Effects of glucosamine hydrochloride combined with non-steroidal anti-inflammatory drugs on symptoms and HSS scores in patients with knee osteoarthritis.
Liu, G; Pan, H; Shi, J; Shi, Q; Wang, F; Wang, J; Zheng, S, 2023
)
0.91

Bioavailability

The improved disintegration and dissolution properties of our prepared ODTs are expected to enhance the bioavailability of the high dose glucosamine and chondroitin sulphate. Reportedly, Rotta-manufactured glucosamines products are more likely to be effective.

ExcerptReferenceRelevance
" As miglitol is well absorbed and acarbose is not, it is suggested that miglitol has a systemic hypoglycaemic effect, probably related to its close structural similarity to glucose, which warrants further investigation."( The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
Foukaridis, GN; Joubert, PH; Venter, HL, 1990
)
0.28
" There was only small faecal excretion, showing an almost complete bioavailability of glucosamine given orally, and the large excretion with the CO2 (82%) showed that glucosamine is to a large extent broken down to smaller fragments."( Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat.
Giachetti, C; Setnikar, I; Zanolo, G, 1984
)
0.27
"0 g) permitted an estimate of 63 +/- 4 (SEM)% bioavailability from urinary recovery of drug, with estimated terminal half-lives of 454 +/- 25 min from minimal data."( Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers.
Altmayer, P; Garrett, ER; Lücker, P; Schuermann, W; Van Peer, A, 1982
)
0.26
" The reported great similarity in apparent first-order absorption rate constants (k) of seven structurally diverse compounds between the two species were obtained."( Similarity in the linear and non-linear oral absorption of drugs between human and rat.
Chiou, WL; Chung, SM; Jeong, HY; Ma, C; Wu, TC, 2000
)
0.31
" The absolute oral bioavailability evaluated on the AUCs of the globulin-incorporated radioactivity was 44%."( Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.
Rovati, LC; Setnikar, I, 2001
)
0.31
" The gut rather than liver is mainly responsible for the first pass metabolism since reduced bioavailability is observed after oral but not intraperitoneal doses."( Single dose pharmacokinetics and bioavailability of glucosamine in the rat.
Aghazadeh-Habashi, A; Jamali, F; Pasutto, F; Sattari, S,
)
0.13
"The purpose of this study was to determine the oral bioavailability and pharmacokinetics of a glucosamine (GL) and the disaccharides of chondroitin sulfate (CS) after single and multiple-dosing of a GL/CS combination (Cosamin, Cosequin)."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs.
Adebowale, A; Du, J; Eddington, ND; Leslie, JL; Liang, Z, 2002
)
0.31
"5 h after 1500 mg dose) and the mean bioavailability of glucosamine after single dosing was approximately 12%."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs.
Adebowale, A; Du, J; Eddington, ND; Leslie, JL; Liang, Z, 2002
)
0.31
" The bioavailability of LMWCS was evaluated by quantifying the total disaccharides found in the plasma following chondroitinase ABC digestion."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse.
Du, J; Eddington, ND; White, N, 2004
)
0.32
"This study provides the first report of the bioavailability of orally administered GL and LMWCS in the horse."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse.
Du, J; Eddington, ND; White, N, 2004
)
0.32
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma.
Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M; Yerramilli, A, 2006
)
0.33
" The method was applied for the determination of glucosamine concentrations in human plasma samples collected from untreated healthy volunteers and, in a separate bioavailability study, to evaluate plasma glucosamine pharmacokinetics profiles after oral administration of crystalline glucosamine sulfate."( Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma.
Barbieri, A; Guardigli, M; Locatelli, M; Persiani, S; Roda, A; Rovati, LC; Sabatini, L; Violante, FS, 2006
)
0.33
"To study single dose pharmacokinetics and bioavailability of the synthetic glucosamine analogue, N-butyryl glucosamine (GLcNBu) after different routes of administration, and also the effect of food following oral doses of GLcNBu in the rat, and stability and absorption of GLcNBu across the rat everted intestine."( Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat.
Aghazadeh-Habashi, A; Anastassiades, T; Carran, J; Ibrahim, A; Jamali, F, 2006
)
0.33
" The gut rather than liver is mainly responsible for the low bioavailability of GLcNBu."( Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat.
Aghazadeh-Habashi, A; Anastassiades, T; Carran, J; Ibrahim, A; Jamali, F, 2006
)
0.33
"Delivery activity of pH-sensitive 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE):cholesteryl hemisuccinate (CHEMS) liposomes was assessed as an in vitro intracellular carrier system to increase the bioavailability of depigmentation actives."( Enhanced depigmenting effects of N-glycosylation inhibitors delivered by pH-sensitive liposomes into HM3KO melanoma cells.
Chang, IS; Choi, H; Hwang, JS; Kim, J; Park, JY,
)
0.13
"The aim of this study was to compare the pharmacokinetics and relative bioavailability of a test and reference formulation of glucosamine sulfate 500 mg after single oral administration in healthy Chinese volunteers."( Bioequivalence of two formulations of glucosamine sulfate 500-mg capsules in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, fasting, two-way crossover study.
Fan, H; Guo, D; Xiao, D; Yang, J; Yu, C; Zhang, J; Zhu, Y; Zou, J, 2009
)
0.35
" Though pharmacokinetic and bioavailability data are limited, use of these supplements has been evaluated for management of osteoarthritis symptoms and modification of disease progression."( Glucosamine and chondroitin sulfate.
Clegg, DO; Miller, KL, 2011
)
0.37
", inconsistency in the chemical potency of some products used, under-dosing of patients as well as variable and erratic bioavailability indices for the lack of GlcN efficacy observed in some studies."( The glucosamine controversy; a pharmacokinetic issue.
Aghazadeh-Habashi, A; Jamali, F, 2011
)
0.37
") bioavailability of glucosamine."( Absorption and bioavailability of glucosamine in the rat.
Aghazadeh-Habashi, A; Gilzad-kohan, MH; Ibrahim, A; Jamali, F, 2012
)
0.38
" In our preceding paper, a series of novel O-6 phosphate N-acetyl (d)-glucosamine prodrugs aimed at improving the oral bioavailability of N-acetyl-(d)-glucosamine as its putative bioactive phosphate form were shown to have greater chondroprotective activity in vitro when compared to the parent agent."( Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
Alcaraz, MJ; Bibbo, R; Caterson, B; Gibert, AT; Hughes, C; McGuigan, C; Rat, S; Roberts, H; Serpi, M; Verson, CR, 2012
)
0.38
" This study was conducted to assess and compare the pharmacokinetic (PK) properties, bioavailability of a newly developed dispersible tablet formulation (test) of glucosamine hydrochloride with those of an established branded capsule formulation (reference) in healthy Chinese adult male volunteers."( Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers.
Feng, W; Liu, M; Tang, Y; Wang, S; Wei, M; Wu, H; Yan, M; Yao, W; Zhao, H, 2012
)
0.38
"Glucosamine, as a dietary supplement for management of osteoarthritis, has a low and erratic oral bioavailability due to its transport-mediated absorption and presystemic loss in liver and GI tract."( Bioavailability enhancement of glucosamine hydrochloride by chitosan.
Betageri, GV; Chow, MS; Huang, M; Lee, B; Qian, S; Wang, Y; Zhang, Q; Zuo, Z, 2013
)
0.39
" Herein, we report the development of a novel assay for the determination of bioavailability of the peptide ester of interest, the anti-inflammatory properties of a glycine-valine ester derivative of GlcN (GVG) as well as its pharmacokinetics under healthy and inflammatory conditions."( The antiinflammatory action and pharmacokinetics of a novel glucosamine-based di-peptide aminosugar.
Gilzad-Kohan, MH; Jamali, F; Kaur, K, 2013
)
0.39
"A pre-column derivatization (with 9-fluorenylmethoxycarbonyl) HPLC assay was developed to study bioavailability of GVG, GlcN or cleaved GlcN in the rats that were cannulated in their right jugular vein for blood collection."( The antiinflammatory action and pharmacokinetics of a novel glucosamine-based di-peptide aminosugar.
Gilzad-Kohan, MH; Jamali, F; Kaur, K, 2013
)
0.39
" Further, the bioavailability of MGC in plasma decreased as compared with mycophenolic acid."( Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery.
Gong, T; Lin, Y; Sun, X; Wang, X; Zeng, Y; Zhang, Z, 2013
)
0.39
" SYSADOA are absorbed in the small intestine with a bioavailability ranging from 5 to 45% and accumulate in articular tissues."( Absorption, distribution and mechanism of action of SYSADOAS.
du Souich, P, 2014
)
0.4
"Paracetamol has an extensive first-pass metabolism that highly affects its bioavailability (BA); thus, dose may be repeated several times a day in order to have longer efficacy."( Glucosamine enhances paracetamol bioavailability by reducing its metabolism.
Al-Jbour, N; Badwan, AA; Ghattas, MA; Matalka, KZ; Qinna, NA; Shubbar, MH, 2015
)
0.42
"A comparison of the relative bioavailability and intensity of penetration of glucosamine sulfate in oral, injection and topical administration of the dosage form Hondroxid Maximum as a cream containing micellar system for transdermal delivery of glucosamine in the experiment by Sprague-Dawley rats was carried out."( [Relative bioavailability of glucosamine after oral, intramuscular and transdermal administration of hondroxid maximum preparation in experiment].
Alexander, A; Li, Y; Mel'nikova, NB; Mukhina, IV; Yasso, B, 2014
)
0.4
" This is the first report in non-human primates of the therapeutic efficacy of a small and orally bioavailable TLR antagonist in severe infection."( Controlling the cytokine storm in severe bacterial diarrhoea with an oral Toll-like receptor 4 antagonist.
Gonwong, S; Imerbsin, R; Islam, D; Khantapura, P; Lombardini, E; Mason, CJ; Neesanant, P; Ruamsap, N; Shaunak, S; Swierczewski, BE; Teo, I; Yongvanitchit, K, 2016
)
0.43
" The purpose of this study was to determine the relative bioavailability of GS for liquid, chewable, and tablet formulations containing GS sulfate or hydrochloride and chondroitin sulfate."( Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs.
Achanta, S; Maxwell, LK; Regier, P,
)
0.13
" Only pCGS is given as a highly bioavailable once daily dose (1500 mg) with a proven pharmacological effect."( A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes.
Bruyère, O; Cooper, C; Kovalenko, V; Kucharz, EJ; Reginster, JY; Szántó, S, 2016
)
0.43
" The aim of this study was to compare the bioavailability of Quatrefolic®, a novel patented (6S)5-MTHF glucosamine salt, with (6S)5-MTHF calcium salt and folic acid in Sprague Dawley rats."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
0.43
"Quatrefolic® has demonstrated an enhanced oral bioavailability in comparison to other reduced folates and to folic acid in rats."( Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats.
Agostinetto, M; Bianchi, D; Miraglia, N; Valoti, E, 2016
)
0.43
" N-acetyl-(d)-glucosamine, a compound that can be modified at the N position, is considered to improve the oral bioavailability of (d)-glucosamine and has been proven to possess greater in vitro chondroprotective activity compared with the parent agent."( Novel biologically active series of N-acetylglucosamine derivatives for the suppressive activities on GAG release.
Cao, T; Dong, L; Jiang, L; Li, Y; Yin, S; Yuan, L, 2016
)
0.43
" oryzae during tempeh-type fermentation of grass pea seeds, and the effect of inoculum composition on the protein level and in vitro protein bioavailability in products."( Proteolysis in tempeh-type products obtained with Rhizopus and Aspergillus strains from grass pea (Lathyrus sativus) seeds.
Starzyńska-Janiszewska, A; Stodolak, B; Wikiera, A,
)
0.13
" In the products, the proteolytic activity (pH 3, 5 and 7), glucosamine, total protein and free amino acids levels, as well as protein in vitro bioavailability and degree of protein hydrolysis were obtained."( Proteolysis in tempeh-type products obtained with Rhizopus and Aspergillus strains from grass pea (Lathyrus sativus) seeds.
Starzyńska-Janiszewska, A; Stodolak, B; Wikiera, A,
)
0.13
" This process resulted in higher in-vitro bioavailability of protein, slightly more efficient protein hydrolysis and higher level of free amino acids, as compared to standard tempeh."( Proteolysis in tempeh-type products obtained with Rhizopus and Aspergillus strains from grass pea (Lathyrus sativus) seeds.
Starzyńska-Janiszewska, A; Stodolak, B; Wikiera, A,
)
0.13
"The improved disintegration and dissolution properties of our prepared ODTs are expected to enhance the bioavailability of the high dose glucosamine and chondroitin sulphate in comparison with conventional tablets, which delineates them as a promising dosage form for the aforementioned nutraceuticals."( Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
Abdel-Hamid, S; Agiba, AM; Geneidi, AS; Nasr, M, 2018
)
0.48
" Only pCGS is given as a highly bioavailable once-daily dose (1500 mg), which consistently delivers the plasma levels of around 10 μmol/L required to inhibit interleukin-1-induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction."( Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment.
Bruyère, O; Cheh Chin, T; Cooper, C; Lwin, M; Mai Hong, N; Reginster, JY; Rojanasthien, S; Saengnipanthkul, S; Srinkapaibulaya, A; Totemchokchyakarn, K; Waikakul, S, 2019
)
0.51
" Only patented crystalline glucosamine sulfate (pCGS) is shown to deliver consistently high glucosamine bioavailability and plasma concentration in humans, which corresponds to demonstrated clinical efficacy."( Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
Al-Daghri, NM; Bruyère, O; Cooper, C; Dennison, EM; Reginster, JY; Rizzoli, R, 2018
)
0.48
"Liposomes are promising systems for the delivery of macromolecules and poorly absorbed drugs, owing to their ability to compartmentalize drugs, their biodegradability and biocompatibility."( Enhancing the Intestinal Permeation of the Chondroprotective Nutraceuticals Glucosamine Sulphate and Chondroitin Sulphate Using Conventional and Modified Liposomes.
Abdel-Hamid, S; Agiba, AM; Eldin, AB; Geneidi, AS; Nasr, M, 2018
)
0.48
" In light of the above, liposomes can be considered promising oral permeation-enhancer system for GluS and CS, which is worthy of future bioavailability experimentation."( Enhancing the Intestinal Permeation of the Chondroprotective Nutraceuticals Glucosamine Sulphate and Chondroitin Sulphate Using Conventional and Modified Liposomes.
Abdel-Hamid, S; Agiba, AM; Eldin, AB; Geneidi, AS; Nasr, M, 2018
)
0.48
" Nevertheless, low bioavailability due to poor solubility limits their practical application."( Asiatic Acid Glucosamine Salt Alleviates Ultraviolet B-induced Photoaging of Human Dermal Fibroblasts and Nude Mouse Skin.
Huang, J; Liu, W; Tu, T; Wang, W; Wu, X; Zhang, W; Zhou, G, 2020
)
0.56
"Although many basic and clinical studies have shown that glucosamine (GlcN) improves osteoarthritis, it has not been widely used in the clinic because its bioavailability is only 6%."( Absorption of glucosamine is improved by considering circadian rhythm and feeding time in rats.
Seto, Y; To, H; Tomonari, M; Yoshihashi, T, 2020
)
0.56
" Reportedly, Rotta-manufactured glucosamine products are more likely to be effective, and a possible explanation is greater bioavailability than other brands."( Variation in the pharmacokinetics of glucosamine in healthy individuals.
Asthana, C; Patel, RP; Peterson, GM; Shastri, MD, 2021
)
0.62

Dosage Studied

Clinically relevant dosing of glucosamine HCl in this large monogastric animal model results in serum and synovial fluid concentrations that are at least 500-fold lower than those reported to modify chondrocyte anabolic and catabolic activities in tissue and cell culture experiments. The studies published to date have been done in small numbers of patients; adequate long-term trials examining the safety, efficacy, and optimal dosage requirements are lacking.

ExcerptRelevanceReference
" Immunization with graded doses of vaccine between 25 to 200 microgram protein indicated a wide range of effective dosage and that a two-dose immunization schedule was superior to a single immunization."( Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
Frasch, CE; Robbins, JD, 1978
)
0.26
" In both types of tissue the parathormone dose-response curves for inhibition of citrate decarboxylation, enhanced hyaluronate synthesis, and increased release of calcium were identical when measured 48 h after treatement."( Effects of parathormone and calcitonin on citrate and hyaluronate metabolism in cultured bone.
Cohn, DV; Luben, RA, 1976
)
0.26
" Teoremac was given for 14 days at a dosage of 420 mg/day."( The therapeutic activity of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid monohydrate glucosamide in rheumatoid arthritis (double blind trial).
Capelli, L; Chianese, U; Giordano, M, 1975
)
0.25
" Injection of protein or glycoprotein precursors into one Rc produced heavy labeling of both Rcs including their processes; a slight labeling of other ganglion compartments was only found after increasing the dosage of the amino acids glycine and leucine."( Transfer of radioactive material between electrically coupled neurons of the leech central nervous system.
Kreutzberg, GW; Rieske, E; Schubert, P, 1975
)
0.25
" The turnover of both lipids exhibited the same the insulin dose-response characteristics in cultures which overexpressed insulin receptors with defective tyrosine kinase domains as in cultures that overexpressed normal human insulin receptors."( Relationship between insulin-mediated turnover of glucosamine-labeled lipids and activity of the insulin receptor tyrosine kinase.
Gottschalk, WK, 1992
)
0.28
"Thirty-six non-insulin-dependent diabetes mellitus (NIDDM) subjects were studied in a double-blind randomized study comparing treatment with a single dosage of 100 mg miglitol or placebo and a single-blind crossover comparison of three test meals in which the carbohydrate contained either 30, 50, or 70% starch, and quantities of fat and protein were kept constant."( alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP, 1992
)
0.28
" These studies suggest the possibility of an extracellular mechanism of action of amiprilose hydrochloride and delineate acceptable dosage ranges for the potential drug."( Effects of amiprilose hydrochloride on the components of human skin equivalents.
Dimitrijevich, SD; Gracy, RW; Hevelone, JC, 1991
)
0.28
" The single-channel conductance was not altered by any of the three inhibitors, and the slopes of log-log dose-response curves at low concentrations and desensitization did not appear to be affected."( Inhibitors of asparagine-linked oligosaccharide processing alter the kinetics of the nicotinic acetylcholine receptor.
Covarrubias, M; Kopta, C; Steinbach, JH, 1989
)
0.28
"01) reduced by miglitol although no reduction in fasting blood glucose, HbA1, plasma lipids, insulin dosage or weight was observed."( Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
Gray, RS; Hillman, RJ; Scott, M, 1989
)
0.28
" Aggregation rates of both older and younger cells were unaffected, as measured by disapperance of single cells, though older cells formed somewhat smaller aggregates at the highest dosage used."( Response of aggregating chick corneal cells to modifiers of N-linked oligosaccharides, endoglycosidase H and deoxymannojirimycin.
Overton, J, 1988
)
0.27
" Nondiabetic mice of the same strain were dosed for 3 and 7 days."( Chronic effects of an alpha-glucosidase inhibitor (Bay o 1248) on intestinal disaccharidase activity in normal and diabetic mice.
Bezerra, J; Bustamante, S; Flores, C; Goda, T; Koldovský, O; Lee, SM, 1987
)
0.27
" Thus, with the dosage schedule employed, Bay-m-1099, but not Bay-o-1248, significantly reduced postprandial increments in plasma insulin."( The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
Gerich, JE; Heiling, V; Kennedy, FP; Miles, JM, 1987
)
0.27
" This might be due to the short duration of the treatment periods or the low dosage of the drug."( Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Arends, J; Willms, BH, 1986
)
0.27
" Further studies should concentrate on the critical dosage which may strike a satisfactory balance between effects and side effects."( The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics.
Federlin, KF; Hillebrand, I; Laube, H; Mehlburger, L,
)
0.13
" A stimulation of sulphate incorporation obeying a linear dose-response curve, was demonstrated in somatomedin-incubated fibroblast and glia cell cultures."( A novel assay for the biosynthesis of sulphated polysaccharide and its application to studies on the effects of somatomedin on cultured cells.
Uthne, K; Wasteson, A; Westermark, B, 1973
)
0.25
" No other hormone altered the FSH dose-response curve."( Proteoglycan production by bovine granulosa cells in vitro occurs in response to fsh.
Ax, RL; Bellin, ME; Lenz, RW; Steadman, LE, 1983
)
0.27
" UV light at a dosage of 135 J/m2 was applied to increase the mutant frequencies in three haploid strains."( Genetic studies on the yeast Saccharomycopsis lipolytica. Inactivation and mutagenesis.
Barth, G; Weber, H, 1983
)
0.27
" The trichloroacetic acid-precipitable protein of rabbit plasma incorporated virtually identical quantities of [4,5-3H]leucine in the absence or presence of TM, under the above dosage regimens, while, at the same time, a large decrease in the incorporation of [2-3H]mannose was observed in the plasma proteins of rabbits treated with TM."( Effect of tunicamycin on appearance of carbohydrate variants of plasminogen in rat and rabbit plasma.
Bretthauer, RK; Castellino, FJ; Powell, JR, 1981
)
0.26
" Dose-response curves for alpha subunit from the different HeLa lines and from tunicamycin- and deoxyglucose-treated cells were sufficiently parallel to indicate similar immunological characteristics."( Glycosylation of the chorionic gonadotropin alpha subunit synthesized by HeLa cells.
Cox, GS, 1981
)
0.26
" These results were also confirmed by the experiments on GAG uptake and degradation and by the dosage of enzymatic activity of two exoglycosidases."( Glycosaminoglycan metabolism in otosclerotic bone cells.
Becchetti, E; Donti, E; Lilli, C; Locci, P; Marinucci, L; Maurizi, M; Paludetti, G; Venti, G, 1996
)
0.29
" During the 12-month study period, the signs and symptoms of the disease were evaluated, as well as the dosage of the urinary pyridinoline."( [The efficacy and safety of glucosamine sulfate in the treatment of gonarthritis].
Battisti, E; Campagna, MS; Franci, B; Gennari, C; Giordano, N; Gonnelli, S; Nardi, P; Palumbo, F; Senesi, M, 1996
)
0.29
" At high dosage the effect of linenscin OC2 was bacteriolytic on Listeria innocua."( Antibacterial and hemolytic activities of linenscin OC2, a hydrophobic substance produced by Brevibacterium linens OC2.
Boucabeille, C; Henckes, G; Mengin-Lecreulx, D; Simonet, JM; van Heijenoort, J, 1997
)
0.3
" Provided careful dosing and surveillance of untoward gastrointestinal effects, non-steroidal antiinflammatory agents still are the drugs of first choice."( [Pharmacotherapy of degenerative joint diseases in dogs].
Klee, S; Ungemach, FR, 1998
)
0.3
" Articles were excluded from critical evaluation for lack of randomization, lack of a control group, 30 or fewer study participants, inconsistent treatment regimen, incomplete dosing information, or incomplete reporting of results."( Glucosamine.
Barclay, TS; McCart, GM; Tsourounis, C, 1998
)
0.3
" The studies published to date have been done in small numbers of patients; adequate long-term trials examining the safety, efficacy, and optimal dosage requirements of glucosamine sulfate are lacking."( Glucosamine sulfate for osteoarthritis.
da Camara, CC; Dowless, GV, 1998
)
0.3
"A selective and specific high performance liquid chromatography method was developed to quantitate glucosamine hydrochloride in raw materials, dosage forms and plasma."( Determination of the nutraceutical, glucosamine hydrochloride, in raw materials, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC.
Adebowale, A; Ashraf, M; Eddington, ND; Leslie, J; Liang, Z, 1999
)
0.3
" These symptoms are usually dose dependent, mild to moderate in severity, occur at the onset of treatment, decline with time and resolve promptly on discontinuation of the drug or with dosage adjustment."( Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott, LJ; Spencer, CM, 2000
)
0.31
"To evaluate miglitol, a new oral alpha-glucosidase inhibitor, and discuss its pharmacology, therapeutics, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy."( Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Baker, DE; Campbell, LK; Campbell, RK, 2000
)
0.31
"5 h after 1500 mg dose) and the mean bioavailability of glucosamine after single dosing was approximately 12%."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs.
Adebowale, A; Du, J; Eddington, ND; Leslie, JL; Liang, Z, 2002
)
0.31
" Application of this knowledge would facilitate development of stable solid dosage forms containing these materials."( Preformulation studies and characterization of proposed chondroprotective agents: glucosamine HCl and chondroitin sulfate.
Ebube, NK; Hahm, H; Mark, W, 2002
)
0.31
" The trends in the results also suggest that, at a dosage of 2,000 mg per day, the majority of improvements are present after eight weeks."( The effect of glucosamine supplementation on people experiencing regular knee pain.
Braham, R; Dawson, B; Goodman, C, 2003
)
0.32
" In addition, glucosamine solid dosage form was exposed to 40 degrees C/75% relative humility for 10 weeks."( Structural identification of nonvolatile dimerization products of glucosamine by gas chromatography-mass spectrometry, liquid chromatography-mass spectrometry, and nuclear magnetic resonance analysis.
Ho, CT; Jun, M; Koetter, U; Lech, S; Shao, Y, 2003
)
0.32
"GL was absorbed after oral dosing with a mean C(max) of 10."( The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse.
Du, J; Eddington, ND; White, N, 2004
)
0.32
"A stability-indicating high performance liquid chromatographic (HPLC) method was developed for the assay of glucosamine in bulk forms and solid dosage formulations."( A stability-indicating HPLC method for the determination of glucosamine in pharmaceutical formulations.
Alluri, R; Koetter, U; Lech, S; Mummert, M; Shao, Y, 2004
)
0.32
" Study medication dosage was equivalent to the dosage of glucosamine taken prior to the study (maximum 1,500 mg/day)."( Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis.
Canvin, J; Cibere, J; Esdaile, JM; Grant, E; Hong, P; Kopec, JA; Pope, J; Robinson, DB; Singer, J; Thorne, A, 2004
)
0.32
" The potential for cytotoxic effects at higher concentrations underscores the importance of establishing appropriate dosage regimens for these aminomonosaccharides."( Comparison of inhibitory effects of glucosamine and mannosamine on bovine articular cartilage degradation in vitro.
Caron, JP; Mello, DM; Nielsen, BD; Orth, MW; Peters, TL, 2004
)
0.32
"To examine the concentration of glucosamine in the synovial fluid and its pharmacokinetics in serum in a large animal model following dosing with glucosamine HCl at clinically relevant levels."( Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses.
Celeste, C; Laverty, S; Marier, JF; Plaas, AH; Sandy, JD; Vachon, P, 2005
)
0.33
" Blood samples were collected before dosing and at 5, 15, 30, 60, 120, 180, 240, 360, 480, and 720 minutes after dosing."( Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses.
Celeste, C; Laverty, S; Marier, JF; Plaas, AH; Sandy, JD; Vachon, P, 2005
)
0.33
"The maximum concentration of glucosamine in serum reached approximately 300 muM ( approximately 50 microg/ml) following IV dosing and approximately 6 microM (approximately 1 microg/ml) following NG dosing."( Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses.
Celeste, C; Laverty, S; Marier, JF; Plaas, AH; Sandy, JD; Vachon, P, 2005
)
0.33
"Clinically relevant dosing of glucosamine HCl in this large monogastric animal model results in serum and synovial fluid concentrations that are at least 500-fold lower than those reported to modify chondrocyte anabolic and catabolic activities in tissue and cell culture experiments."( Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses.
Celeste, C; Laverty, S; Marier, JF; Plaas, AH; Sandy, JD; Vachon, P, 2005
)
0.33
" A cell culture model of the gastric epithelial cell surface would prove useful for biopharmaceutical screening of new chemical entities and dosage forms."( A collagen IV matrix is required for guinea pig gastric epithelial cell monolayers to provide an optimal model of the stomach surface for biopharmaceutical screening.
Coombes, AG; Hanson, PJ; Kavvada, KM; Moore, VA; Murray, JG, 2005
)
0.33
" The patients were randomly divided into 2 groups: 45 patients of the study group taking 1 tablet ARTRA 2 times a day within the first month, than 1 tablet a day within the following 5 months and diclofenac sodium 50 mg 2 times a day with gradual decrease of the dosage as the pain was decreasing; 45 patients of the control group taking only diclofenac sodium 50 mg twice a day during 6 months."( [Combined medication ARTRA in the treatment of osteoarthrosis].
Alekseeva, LI; Benevolenskaia, LI; Chichasova, NV; Mendel', OI; Nasonov, EL, 2005
)
0.33
" Regular intake of ARTRA helps decrease NSAIDS dosage or discontinue intake in many cases."( [Combined medication ARTRA in the treatment of osteoarthrosis].
Alekseeva, LI; Benevolenskaia, LI; Chichasova, NV; Mendel', OI; Nasonov, EL, 2005
)
0.33
"To select a high-quality chondroitin dosage form and/or an appropriate source of sodium chondroitin for the National Institutes of Health's Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)."( Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial.
Barnhill, JG; Clegg, DO; Fye, CL; Harris, CL; Reda, DJ; Williams, DW,
)
0.13
" Based on the dose-response experiments, treatments included fetal bovine serum (FBS) control, 15 ng/ml IL-1, and 15 ng/ml IL-1 with the addition of 10 microg/ml GLN and 20 microg/ml CS."( Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate.
Caron, JP; Chan, PS; Orth, MW, 2006
)
0.33
"HCl exhibited antitumor activity against Sarcoma 180 in Kunming mice at dosage of 125-500 mg/kg, dose of 250 mg/kg being the best."( Antitumor activities of D-glucosamine and its derivatives.
Han, BQ; Liu, WS; Peng, YF; Wang, DF; Zhang, L, 2006
)
0.33
" Plasma glucosamine pharmacokinetics after oral dosing were determined in each subject using a high-performance liquid chromatography method."( Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects.
Bronstein, JA; Crandon, SK; Hall, G; Hortin, GL; Karne, RJ; Muniyappa, R; Quon, MJ; Ver, MR, 2006
)
0.33
"The findings of this study indicate that glucosamine sulfate at the oral once-daily dosage of 1,500 mg is more effective than placebo in treating knee OA symptoms."( Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator.
Araújo, D; Benito, P; Blanco, FJ; Branco, J; Del Carmen Trabado, M; Figueroa, M; Herrero-Beaumont, G; Ivorra, JA; Laffon, A; Marenco, JL; Martín-Mola, E; Paulino, J; Porto, A, 2007
)
0.34
"A 3 months', post-marketing, randomised, double-blinded, placebo-controlled, clinical trial was performed with parallel groups of 66 patients over 40 years of age with joint pain of long duration receiving either recommend dosage (1500 mg per day) of glucosamine sulphate or placebo."( [The effect of glucosamine sulphate on the blood levels of cholesterol or triglycerides--a clinical study].
Hviid, T; Hyllested-Winge, JL; Østergaard, K, 2007
)
0.34
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
"A column high-performance liquid chromatography (HPLC) method was developed for the determination of glucosamine in dosage forms."( Development of a simple and sensitive high-performance liquid chromatography method for determination of glucosamine in pharmaceutical formulations.
Ansarin, M; Ghaderi, F; Nemati, M; Valizadeh, H,
)
0.13
" Plasma samples were collected before dosing and at 5, 15, 30, 60, 120, 360, 480 and 720 min after dosing."( Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride.
Beauchamp, G; Beaudry, F; Laverty, S; Meulyzer, M; Richard, H; Vachon, P; Vinardell, T, 2008
)
0.35
" Before dosing and after each monthly treatment during the five months, knee joints Cartilage specimens from 5 guinea pigs each group were examined through histopathological method (H."( [Effect of cartilage protective agents on histopathological, histochemical features of articular cartilage and serum level of aggrecan in Hartley guinea pigs].
Dong, M; Hong, X; Wang, N; Xiao, P, 2008
)
0.35
" Synovial fluid (SF) samples were collected within 48 h before dosing and 1, 6 and 12h post-dosing."( Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride.
Beauchamp, G; Beaudry, F; Laverty, S; Meulyzer, M; Richard, H; Vachon, P; Vinardell, T, 2009
)
0.35
"2 as the background electrolyte; voltage 30 kV; 25 degrees C), GlAm (migrating as glucosaminium cation) was well separated from K(+) that could occur in the dosage forms as excipient."( Fast assay of glucosamine in pharmaceuticals and nutraceuticals by capillary zone electrophoresis with contactless conductivity detection.
Jác, P; Los, P; Polásek, M; Pospísilová, M; Spácil, Z, 2008
)
0.35
"As part of the National Institutes of Health (NIH)-sponsored Glucosamine/Chondroitin sulfate Arthritis Intervention Trial (GAIT) our objective here was to examine (1) the pharmacokinetics (PK) of glucosamine (GlcN) and chondroitin sulfate (CS) when taken separately or in combination as a single dose in normal individuals (n=29) and (2) the PK of GlcN and CS when taken as a single dose after 3 months daily dosing with GlcN, CS or GlcN+CS, in patients with symptomatic knee pain (n=28)."( The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.
Barnhill, JG; Clegg, DO; Harris, CL; Hua, C; Jackson, CG; Kim-Rolands, S; Plaas, AH; Sandy, JD, 2010
)
0.36
" The hydrodynamic size and disaccharide composition of CS chains in the circulation and dosage samples was determined by Superose 6 chromatography and FACE."( The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.
Barnhill, JG; Clegg, DO; Harris, CL; Hua, C; Jackson, CG; Kim-Rolands, S; Plaas, AH; Sandy, JD, 2010
)
0.36
" On the other hand, the Cmax (single-dose study) and AUC values (multiple-dose study) for ingested GlcN were significantly reduced by combination dosing with CS, relative to GlcN dosing alone."( The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.
Barnhill, JG; Clegg, DO; Harris, CL; Hua, C; Jackson, CG; Kim-Rolands, S; Plaas, AH; Sandy, JD, 2010
)
0.36
" Moreover, since combined dosing of GlcN with CS was found to reduce the plasma levels seen with GlcN dosing alone, any improved pain relief by combination dosing cannot be explained by higher circulating concentrations of GlcN."( The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.
Barnhill, JG; Clegg, DO; Harris, CL; Hua, C; Jackson, CG; Kim-Rolands, S; Plaas, AH; Sandy, JD, 2010
)
0.36
" Lean Zucker rats were dosed orally for 6 weeks with glucosamine hydrochloride at doses (0-600 mg/kg/day) that produced peak serum concentrations of <1-35 μM, spanning the human exposure range."( Oral glucosamine increases expression of transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF) mRNA in rat cartilage and kidney: implications for human efficacy and toxicity.
Ali, AA; Allaben, WT; Badgley, HL; Leakey, JE; Lewis, SM, 2011
)
0.37
" It can sometimes enable us to decrease the dosage of others treatment such as NSAIDs."( [Role of slow-acting anti-arthritic agents in osteoarthritis (chondroitin sulfate, glucosamine, hyaluronic acid)].
Aubry-Rozier, B, 2012
)
0.38
" Cancer cells are highly attractive to glucose [with a nanosize bimolecular structure 1nm] as an energy source more than normal cell and nanosized therapeutics due to possessing different pharmacokinetic and pharmacodynamic have advantageous over classical dosage forms in cancer therapy."( Nanosized tamoxifen-porphyrin-glucose [TPG] conjugate: novel selective anti-breast-cancer agent, synthesis and in vitro evaluations.
Aghasadeghi, MR; Alaei-Beirami, M; Alavidjeh, MS; Amanlou, M; Arabzadeh, AJ; Ardestani, MS; Dashtbani-Roozbehani, A; Delbaz, SA; Ebrahimi, SE; Ghorbani, M; Hajmohammadi, M; Heidari, Z; Hekmat, S; Moghaddam, HF; Sadat, SM; Saraji, AA; Siadat, SD, 2013
)
0.39
"Fourteen food supplements and one medicine containing glucosamine and formulated as film-coated tablets and capsules, were evaluated with different tests, including uniformity of mass and dosage units, disintegration, identification and assay of glucosamine with a validated HPLC-ELSD method."( [Glucosamine preparations on the Belgian market: a comparative study].
Corthout, J; Fierens, C, 2012
)
0.38
" Nevertheless, the agent needs a high dosage in treatment, following some side effects."( Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery.
Gong, T; Lin, Y; Sun, X; Wang, X; Zeng, Y; Zhang, Z, 2013
)
0.39
" If the data extrapolated to humans, a higher than the commonly tested 1500 mg/kg dosage regimen may provide more clear treatment outcomes."( Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis.
Aghazadeh-Habashi, A; Asghar, W; Jamali, F; Kohan, MH, 2014
)
0.4
" The 350 μg dosage of GlcN had the most significant positive impact on all components of the modified Mankin score."( Intra-articular delivery of glucosamine for treatment of experimental osteoarthritis created by a medial meniscectomy in a rat model.
Bingham, C; Coburn, J; Elisseeff, J; Gibson, M; Li, H; Moroni, L; Nahas, Z; Yarema, K, 2014
)
0.4
"A comparison of the relative bioavailability and intensity of penetration of glucosamine sulfate in oral, injection and topical administration of the dosage form Hondroxid Maximum as a cream containing micellar system for transdermal delivery of glucosamine in the experiment by Sprague-Dawley rats was carried out."( [Relative bioavailability of glucosamine after oral, intramuscular and transdermal administration of hondroxid maximum preparation in experiment].
Alexander, A; Li, Y; Mel'nikova, NB; Mukhina, IV; Yasso, B, 2014
)
0.4
" Although further research is required to fully understand the dual effects of glucosamine, dosage and duration of glucosamine treatment are clear contributing factors towards the line of beneficial reward-to-risk action."( Beneficial reward-to-risk action of glucosamine during pathogenesis of osteoarthritis.
Ahn, C; Jin, EJ; Kang, YH; Kim, D; Park, S; Song, J, 2015
)
0.42
" Examination of the evidence for the prescription patented crystalline GS (pCGS) formulation at a dose of 1500mg once-daily demonstrates superiority over other GS and glucosamine hydrochloride (GH) formulations and dosage regimens."( Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Altman, RD; Bruyère, O; Reginster, JY, 2016
)
0.43
"The improved disintegration and dissolution properties of our prepared ODTs are expected to enhance the bioavailability of the high dose glucosamine and chondroitin sulphate in comparison with conventional tablets, which delineates them as a promising dosage form for the aforementioned nutraceuticals."( Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
Abdel-Hamid, S; Agiba, AM; Geneidi, AS; Nasr, M, 2018
)
0.48
" Following a single intravitreal injection, the proposed TA-SA-Glu hydrogel hardly caused apparent retinal toxicity at a dosage of 69 nmol per eye."( Glycosylation-enhanced biocompatibility of the supramolecular hydrogel of an anti-inflammatory drug for topical suppression of inflammation.
Lei, L; Li, X; Song, Q; Xiong, T; Zhang, R; Zhou, Y, 2018
)
0.48
" Failure to employ bolus dosing may also be a factor in the null results observed in the GAIT study and other trials."( Glucosamine for the Treatment of Osteoarthritis: The Time Has Come for Higher-Dose Trials.
DiNicolantonio, JJ; McCarty, MF; O'Keefe, JH, 2019
)
0.51
" More than 2-fold increase in area under the curve from 0 to 24 h from the dispersions was noticed on the third day of oral dosing to animals."( Glucosamine-paracetamol spray-dried solid dispersions with maximized intrinsic dissolution rate, bioavailability and decreased levels of in vivo toxic metabolites.
Abourehab, MA; Ali, AMA; Alrobaian, MM; Hamaidi, M; Khames, A, 2018
)
0.48
" However, its use and the dosage range applied have been limited by severe side effects (e."( GMDTC Chelating Agent Attenuates Cisplatin-Induced Systemic Toxicity without Affecting Antitumor Efficacy.
Aga, DS; Chen, X; Ge, Y; Hu, W; Olson, JR; Ren, X; Sun, W; Tang, X; Zheng, N; Zhu, J, 2019
)
0.51
" In the present study, we developed a dry powder inhaler dosage form containing gefitinib loaded glucosamine targeted solid lipid nanopaticles (Gef-G-SLNs) to locally transfer anticancer agent to the lung tumor."( Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.
Mirian, M; Rostami, M; Satari, N; Taymouri, S; Varshosaz, J, 2020
)
0.56
" The results indicate that a short-term supplementation of a low dosage CGM exerted superior beneficial effects than a high-dosage CHN-GLN combination in alleviating the pain and symptoms of OA subjects."( Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial.
Khanna, A; Krishnakumar, IM; Kunnumakkara, AB; Maliakel, B; Mohanan, R; Smina, TP; Thomas, JV, 2021
)
0.62
" In a nut shell this modified new dosage from can be best alternative to other conventional options that owe lot of demerits."( Formulation, characterization of glucosamine loaded transfersomes and in vivo evaluation using papain induced arthritis model.
Ansari, SF; Rasheed, MS; Shahzadi, I, 2022
)
0.72
" One hundred and fifty overweight or obese cases were treated, divided into two groups for a period of 90 days at the dosage of 3 g/day."( A Randomized Double-Blind Placebo-Controlled Clinical Study to Evaluate the Effect on the Weight of a Medical Device with Polyglucosamine L112 in a Group of Overweight and Obese Subjects.
Cazzola, R; Cestaro, B; Della Porta, M; Gasparri, C; Lombardoni, F; Nichetti, M; Patelli, Z; Perna, S; Pistolesi, E; Rondanelli, M, 2023
)
0.91
" However, APOE ε4 dosage and baseline cognitive function did not significantly modify the relationships of glucosamine use with incident vascular dementia or Alzheimer's disease (All P-interactions > 0."( Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population.
He, P; Liu, M; Qin, X; Wu, Q; Yang, S; Ye, Z; Zhang, Y; Zhou, C, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
D-glucosamineAn amino sugar whose structure comprises D-glucose having an amino substituent at position 2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Digestion and absorption1724
Digestion1223
Digestion of dietary carbohydrate611
Amino Sugar Metabolism1731
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
Tay-Sachs Disease1731
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
Chitobiose Degradation47
Aminosugars metabolism ( Aminosugars metabolism )1529
Biochemical pathways: part I0466

Bioassays (103)

Assay IDTitleYearJournalArticle
AID307618Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 250 mg/kg after 3 hrs relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID266424Increase in plasma glutamate oxaloacetate transaminase level in Wistar rat at 1 g/kg, ip after 12 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID250581Concentration of C24:0 ceramide in plasma of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID677455Cytotoxicity against bovine articular chondrocytes assessed as cell viability at 10 mM by MTT assay relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID1104998Antifungal activity against Poria placenta FPRL 280 assessed as mycelial growth inhibition at 0.75 x 10'-4 mol/ml after 9 days relative to control2011Pest management science, Mar, Volume: 67, Issue:3
Synthesis of D-glucosamine quaternary ammonium derivatives and evaluation of their antifungal activity together with aminodeoxyglucose derivatives against two wood fungi Coriolus versicolor and Poria placenta: structure-activity relationships.
AID426795Antiinvasive activity in human HT1080 cells at 60 ug/ml after 48 hrs2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID250529Concentration of C16:0 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID266429Increase in plasma glutamate pyruvate transaminase level in Wistar rat at 1 g/kg, ip after 12 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID266421Increase in plasma glutamate oxaloacetate transaminase level in Wistar rat at 1 g/kg, ip after 1.5 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID540235Phospholipidosis-negative literature compound
AID250577Concentration of C22:1 ceramide in plasma of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID1299043Cytotoxic activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID677452Antidegenerative activity against bovine cartilage explant assessed as inhibition of IL1-induced of GAG release at 10 mM for 1 day before IL-1 treatment measured after 6 days by colorimetric analysis relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID387709Inhibition of LPS-stimulated TNFalpha production in mouse RAW264.7 cells treated 1 hr before LPS challenge after 24 hrs by ELISA2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-kappaB and MAPK expressions.
AID1299068Cytotoxic activity against human MCF10A cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID250573Concentration of C18:0 ceramide in plasma of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250537Concentration of C22:1 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250576Concentration of C22:0 ceramide in plasma of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID677450Cytotoxicity against human articular chondrocytes assessed as metabolic activity at 250 uM by WST-1 assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID250584Concentration of C24:2 ceramide in plasma of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250571Concentration of C16:0 ceramide in plasma of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID677459Antidegenerative activity against human cartilage explant assessed as inhibition of IL1-induced of GAG release at 250 uM for 1 day before IL-1 treatment measured after 6 days by colorimetric analysis relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID250539Concentration of C22:2 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250582Concentration of C24:1 ceramide in plasma of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID266426Increase in plasma glutamate pyruvate transaminase level in Wistar rat at 1 g/kg, ip after 1.5 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID1105000Antifungal activity against Trametes versicolor Quel. CTB 863-A assessed as mycelial growth inhibition at 1.5 x 10'-4 mol/ml after 9 days relative to control2011Pest management science, Mar, Volume: 67, Issue:3
Synthesis of D-glucosamine quaternary ammonium derivatives and evaluation of their antifungal activity together with aminodeoxyglucose derivatives against two wood fungi Coriolus versicolor and Poria placenta: structure-activity relationships.
AID266423Increase in plasma glutamate oxaloacetate transaminase level in Wistar rat at 1 g/kg, ip after 6 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID250545Concentration of C24:2 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250579Concentration of C22:2 ceramide in plasma of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID266430Increase in plasma glutamate pyruvate transaminase level in Wistar rat at 1 g/kg, ip after 24 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID731122Induction of Heparan-alpha-glucosaminide N-acetyltransferase N273K mutant activity in immortalized skin fibroblasts derived from patient at 14 mM after 5 days relative to non-treated cells2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID266435Increase in hepatic vitamin C level in Wistar rat at 1 g/kg, ip after 24 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID250544Concentration of C24:2 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID298842Effect on osteocalcin secretion in human MG63 cells after 4 days2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect.
AID362966Chondroprotective activity in bovine articular cartilage explant cultures assessed as reduction in IL1-induced glycosaminoglycan release at 0.1 mM after 96 hrs2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID1105001Antifungal activity against Trametes versicolor Quel. CTB 863-A assessed as mycelial growth inhibition at 1 x 10'-4 mol/ml after 9 days relative to control2011Pest management science, Mar, Volume: 67, Issue:3
Synthesis of D-glucosamine quaternary ammonium derivatives and evaluation of their antifungal activity together with aminodeoxyglucose derivatives against two wood fungi Coriolus versicolor and Poria placenta: structure-activity relationships.
AID266434Increase in hepatic vitamin C level in Wistar rat at 1 g/kg, ip after 12 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID298847Effect on alkaline phosphatase activity in human MG63 cells at 100 ug/mL after 24 hrs2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect.
AID266432Increase in hepatic vitamin C level in Wistar rat at 1 g/kg, ip after 3 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID426776Inhibition of MMP2 gelatinolytic activity in phorbol myristate acetate-stimulated human HT1080 cells at 60 ug/ml by gelatin zymography relative to control2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.
AID426777Inhibition of MMP9 gelatinolytic activity in phorbol myristate acetate-stimulated human HT1080 cells at 60 ug/ml by gelatin zymography relative to control2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.
AID307622Antiarthritic activity against Mycobacterium tuberculosis-induced rat arthritic model assessed as inhibition of chronic phase inflammation at 250 mg/kg relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID250574Concentration of C20:0 ceramide in plasma of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250218Plasma GOT level was observed after 24 hr of D-galactosamine administration at 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID677451Cytotoxicity against human articular chondrocytes assessed as metabolic activity at 10 uM by WST-1 assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID250533Concentration of C20:0 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID387710Inhibition of LPS-stimulated IL1-beta production in mouse RAW264.7 cells treated 1 hr before LPS challenge after 24 hrs by ELISA2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-kappaB and MAPK expressions.
AID250530Concentration of C18:0 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID362962Chondroprotective activity in bovine articular cartilage explant cultures assessed as reduction in IL1-induced glycosaminoglycan release at 10 mM after 96 hrs relative to control2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID250535Concentration of C22:0 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID2941Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and evaluation of novel bacterial rRNA-binding benzimidazoles by mass spectrometry.
AID250534Concentration of C22:0 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID307619Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 250 mg/kg after 4 hrs relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID250219Plasma GPT level was observed after 18 hr of D-galactosamine administration at 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250540Concentration of C24:0 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250531Concentration of C18:0 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID362963Chondroprotective activity in bovine articular cartilage explant cultures assessed as reduction in IL1-induced glycosaminoglycan release at 10 mM after 96 hrs2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID266438Increase in phosphorylated p38 MAPK level in Wistar rat at 1 g/kg, ip after 6 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID250570Concentration of C16:0 ceramide in plasma of D-galactosamine treated rats after 18 h at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID250583Concentration of C24:1 ceramide in plasma of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID677457Cytotoxicity against bovine articular chondrocytes assessed as cell viability at 0.1 mM by MTT assay relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID266436Increase in phosphorylated JNK level in Wistar rat at 1 g/kg, ip after 3 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID677453Antidegenerative activity against bovine cartilage explant assessed as inhibition of IL1-induced of GAG release at 1 mM for 1 day before IL-1 treatment measured after 6 days by colorimetric analysis relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID677454Antidegenerative activity against bovine cartilage explant assessed as inhibition of IL1-induced of GAG release at 0.1 mM for 1 day before IL-1 treatment measured after 6 days by colorimetric analysis relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID298844Inhibition of lipopolysaccharide stimulated TNFalpha synthesis in mouse RAW 264.7 cells2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect.
AID250542Concentration of C24:1 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250572Concentration of C18:0 ceramide in plasma of D-galactosamine treated rats after 18 h at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID1104999Antifungal activity against Poria placenta FPRL 280 assessed as mycelial growth inhibition at 0.5 x 10'-4 mol/ml after 9 days relative to control2011Pest management science, Mar, Volume: 67, Issue:3
Synthesis of D-glucosamine quaternary ammonium derivatives and evaluation of their antifungal activity together with aminodeoxyglucose derivatives against two wood fungi Coriolus versicolor and Poria placenta: structure-activity relationships.
AID250580Concentration of C24:0 ceramide in plasma of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250536Concentration of C22:1 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID362968Cytotoxicity against bovine chondrocytes at 0.1 mM after 96 hrs by MTT cell viability assay2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID250532Concentration of C20:0 ceramide in liver of D-galactosamine treated rats after 18 h at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID362965Cytotoxicity against bovine chondrocytes at 1 mM after 96 hrs by MTT cell viability assay2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID250217Plasma GOT level was observed after 18 hr of D-galactosamine administration at 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID387711Inhibition of LPS-stimulated PGE2 production in mouse RAW264.7 cells treated 1 hr before LPS challenge after 24 hrs by ELISA2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-kappaB and MAPK expressions.
AID250543Concentration of C24:1 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID266437Increase in phosphorylated ERK level in Wistar rat at 1 g/kg, ip after 3 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID362960Chondroprotective activity in bovine articular cartilage explant cultures assessed as reduction in IL1-induced glycosaminoglycan release at 1 mM after 96 hrs2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID266433Increase in hepatic vitamin C level in Wistar rat at 1 g/kg, ip after 6 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID266422Increase in plasma glutamate oxaloacetate transaminase level in Wistar rat at 1 g/kg, ip after 3 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID266431Increase in hepatic vitamin C level in Wistar rat at 1 g/kg, ip after 1.5 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID677458Antidegenerative activity against human cartilage explant assessed as inhibition of IL1-induced of GAG release at 10 uM for 1 day before IL-1 treatment measured after 6 days by colorimetric analysis relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID362961Cytotoxicity against bovine chondrocytes at 10 mM after 96 hrs by MTT cell viability assay2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID250538Concentration of C22:2 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID362964Chondroprotective activity in bovine articular cartilage explant cultures assessed as reduction in IL1-induced glycosaminoglycan release at 1 mM after 96 hrs relative to control2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID250578Concentration of C22:2 ceramide in plasma of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID266428Increase in plasma glutamate pyruvate transaminase level in Wistar rat at 1 g/kg, ip after 6 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID266425Increase in plasma glutamate oxaloacetate transaminase level in Wistar rat at 1 g/kg, ip after 24 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID362967Chondroprotective activity in bovine articular cartilage explant cultures assessed as reduction in IL1-induced glycosaminoglycan release at 0.1 mM after 96 hrs relative to control2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery.
AID266427Increase in plasma glutamate pyruvate transaminase level in Wistar rat at 1 g/kg, ip after 3 hrs relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver.
AID250575Concentration of C20:0 ceramide in plasma of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250541Concentration of C24:0 ceramide in liver of D-galactosamine treated rats after 24 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID387720Inhibition of LPS-stimulated IL6 production in mouse RAW264.7 cells treated 1 hr before LPS challenge after 24 hrs by ELISA2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-kappaB and MAPK expressions.
AID677456Cytotoxicity against bovine articular chondrocytes assessed as cell viability at 1 mM by MTT assay relative to control2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
AID250528Concentration of C16:0 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
AID250220Plasma GPT level was observed after 24 hr of D-galactosamine administration at 1 g/kg intraperitoneally2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9,923)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906094 (61.41)18.7374
1990's953 (9.60)18.2507
2000's1283 (12.93)29.6817
2010's1234 (12.44)24.3611
2020's359 (3.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials280 (2.73%)5.53%
Reviews441 (4.29%)6.00%
Case Studies95 (0.92%)4.05%
Observational6 (0.06%)0.25%
Other9,451 (92.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]